Dicot presents positive results from the first part of its phase 1 clinical study showing that LIB-01 has a very good safety profile. There were no serious adverse effects. The results also show that the drug is well absorbed in the body, which puts the company in a strong position for clinical phase 2. The primary objective of Dicot's phase 1 study is to investigate the safety of the potency drug candidate LIB-01 in humans.

The study is double-blind and placebo-controlled and consists of two parts: SAD and MAD. The SAD part studies increasing single doses of LIB-01 regarding safety parameters such as adverse effects as well as how well the drug is absorbed in the body. In the MAD part, the same assessments are done, but with repeated dosing.

The company announces the first overall results from the SAD part, showing a very good safety profile. The company announced the first overall results from the MAD, the second and final part of the phase 1 study, will be published in the second quarter of 2024.